Cibotercept
Cibotercept (KER-012) is a novel, modified, investigational activin receptor type IIB (ActRIIB) ligand trap designed to target select TGF-β ligands, including activins A and B, GDFs 8 and 11, to rebalance the defective activin receptor type II signaling observed in PAH[1][2].
Product Specifications
CAS Number
2769700-97-0
Product Name Alternative
KER-012
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cibotercept.html
Purity
99.85
References & Citations
[1]Cibotercept|[2]Sebastien J. Sannajust, et al. Nonclinical Assessment of Cibotercept (KER-012), A Novel Modified ActRIIB Ligand Trap, For the Treatment of Pulmonary Arterial Hypertension.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
21478061 1.0 µg DNA
GGT4P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 
MBS1460665-01 0.02 mg (E-Coli)
Recombinant Staphylococcus aureus Putative acetyl-CoA C-acetyltransferase vraB (vraB)
Sign In for Pricing
View Details MBS1460665-02 0.02 mg (Yeast)
Recombinant Staphylococcus aureus Putative acetyl-CoA C-acetyltransferase vraB (vraB)
Sign In for Pricing
View Details